Back to Journals
Journal of Hepatocellular Carcinoma
Call For Papers
The Journal of Hepatocellular Carcinoma is indexed online:
- PubMed and PubMed Central (J Hepatocell Carcinoma)
- Science Citation Index Expanded (also known as SciSearch®)
- Journal Citation Reports/Science Edition
- Current Contents®/Life Sciences
- Embase, from 2018 (Correct as at September 10, 2018)
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
Journal Impact Factor: 4.655
Call for Papers: Addressing global differences in HCC risk factors and management strategies
The Journal of Hepatocellular Carcinoma is encouraging papers addressing global diversity in HCC risk factors and their effect on outcomes. Although significant advances have been made in multidisciplinary and individualized screening and treatments for HCC, such sophisticated methods are relatively expensive and therefore remain beyond the reach of many patients in less economically developed countries where local resources and healthcare budget are limited. To address the global differences in treatment provision, the journal Editors are seeking to publish multidisciplinary clinical and translational studies, cost-effective screening and treatment strategies and consensus statements, including those which consider available local resources.
Authors interested in publishing country-specific guidelines and conference proceedings may be eligible for a discounted publication processing fee. Such requests will be assessed on a case-by-case basis. Please contact Sophie Fagg at Sophie.Fagg@tandf.co.uk with your query prior to submission.
What is the advantage to you of publishing in the Journal of Hepatocellular Carcinoma?
- It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
- Although the Journal of Hepatocellular Carcinoma receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
- The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. The Journal of Hepatocellular Carcinoma has a quicker turnaround time than this. Generally, peer review is complete within 4-7 weeks and the editor’s decision within 2-14 days of this. Therefore, your paper could potentially be peer-reviewed and finally accepted in 6-9 weeks.
- Many authors have found that our peer reviewer’s comments substantially add to their final papers.
To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.
The Journal of Hepatocellular Carcinoma is indexed on PubMed Central (title abbreviation J Hepatocell Carcinoma). All published papers in this journal are submitted to PubMed for indexing straight away.
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.
Dr Ahmed Kaseb
Journal of Hepatocellular Carcinoma